Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Fast Forward

Bill Nye Thinks Israel Is Leading The World In Medical Marijuana Research

People are getting high in the Holy Land for a good cause.

In a recent episode of “Bill Nye Saves the World” in which Nye explore medical marijuana, he sends a correspondent to Israel for a segment called “How is Israel healing the world with marijuana.”

The episode highlights the progress Israel has made in medical marijuana research, noting that there are significantly fewer regulatory hurdles than in the United States.

The company Tikun Olam operates the largest cannabis farm in Israel, and it’s licensed by the Israeli government. Tikkun Olam CEO Aharon Lutzky explains that the cooperation between the Israeli government and private industry fosters success in finding ways cannabis can help patients struggling with conditions such as cancer, Crohn’s and colitis, PTSD, epilepsy and Parkinson’s disease.

Nye notes that the situation is very different in the U.S. because the Drug Enforcement Agency doesn’t believe cannabis has medical value, and therefore classifies it as a Schedule 1 drug, making it illegal to grow it for the purpose of medical studies.

“It is literally easier to study meth,” Nye claimed.

Israeli organic chemist Raphael Mechoulam was the first to isolate marijuana’s THC compound for scientific study more than 50 years ago. In 1996, Israel began its national medical marijuana program, the first one in the world.

Contact Avichai Scher at scher@forward.com or on Twitter, @avi_scher

A message from our CEO & publisher Rachel Fishman Feddersen

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.

At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and the protests on college campuses.

Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.

—  Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at editorial@forward.com, subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.

Exit mobile version